XML 35 R25.htm IDEA: XBRL DOCUMENT
v3.21.2

Revenues (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2021
Revenue from Contract with Customer [Abstract] |
Disaggregation of revenue by product and by geographic area | Revenues were as follows (in millions):
|  | Three months ended September 30,
|  | 2021 |  | 2020
|  | U.S. |  | ROW |  | Total |  | U.S. |  | ROW |  | Total
Enbrel® (etanercept) |  | $ | 1,263 |  |  | $ | 26 |  |  | $ | 1,289 |  |  | $ | 1,289 |  |  | $ | 36 |  |  | $ | 1,325 |
Prolia® (denosumab) |  | 530 |  |  | 273 |  |  | 803 |  |  | 478 |  |  | 223 |  |  | 701 |
Otezla® (apremilast) |  | 495 |  |  | 114 |  |  | 609 |  |  | 439 |  |  | 99 |  |  | 538 |
XGEVA® (denosumab) |  | 372 |  |  | 145 |  |  | 517 |  |  | 363 |  |  | 118 |  |  | 481 |
Neulasta® (pegfilgrastim) |  | 360 |  |  | 55 |  |  | 415 |  |  | 484 |  |  | 71 |  |  | 555 |
Aranesp® (darbepoetin alfa) |  | 149 |  |  | 247 |  |  | 396 |  |  | 158 |  |  | 226 |  |  | 384 |
Repatha® (evolocumab) |  | 139 |  |  | 133 |  |  | 272 |  |  | 92 |  |  | 113 |  |  | 205 |
KYPROLIS® (carfilzomib) |  | 198 |  |  | 95 |  |  | 293 |  |  | 173 |  |  | 87 |  |  | 260 |
Other products |  | 1,052 |  |  | 674 |  |  | 1,726 |  |  | 1,142 |  |  | 513 |  |  | 1,655 |
Total product sales(1) |  | $ | 4,558 |  |  | $ | 1,762 |  |  | 6,320 |  |  | $ | 4,618 |  |  | $ | 1,486 |  |  | 6,104 |
Other revenues |  |  |  |  |  | 386 |  |  |  |  |  |  | 319 |
Total revenues |  |  |  |  |  | $ | 6,706 |  |  |  |  |  |  | $ | 6,423 |
|  | Nine months ended September 30,
|  | 2021 |  | 2020
|  | U.S. |  | ROW |  | Total |  | U.S. |  | ROW |  | Total
ENBREL |  | $ | 3,270 |  |  | $ | 87 |  |  | $ | 3,357 |  |  | $ | 3,619 |  |  | $ | 105 |  |  | $ | 3,724 |
Prolia® |  | 1,569 |  |  | 806 |  |  | 2,375 |  |  | 1,341 |  |  | 673 |  |  | 2,014 |
Otezla® |  | 1,284 |  |  | 335 |  |  | 1,619 |  |  | 1,280 |  |  | 298 |  |  | 1,578 |
XGEVA® |  | 1,061 |  |  | 412 |  |  | 1,473 |  |  | 1,036 |  |  | 361 |  |  | 1,397 |
Neulasta® |  | 1,215 |  |  | 168 |  |  | 1,383 |  |  | 1,538 |  |  | 219 |  |  | 1,757 |
Aranesp® |  | 409 |  |  | 709 |  |  | 1,118 |  |  | 489 |  |  | 704 |  |  | 1,193 |
Repatha® |  | 421 |  |  | 423 |  |  | 844 |  |  | 331 |  |  | 303 |  |  | 634 |
KYPROLIS® |  | 547 |  |  | 277 |  |  | 824 |  |  | 527 |  |  | 266 |  |  | 793 |
Other products |  | 3,059 |  |  | 1,974 |  |  | 5,033 |  |  | 3,164 |  |  | 1,652 |  |  | 4,816 |
Total product sales(1) |  | $ | 12,835 |  |  | $ | 5,191 |  |  | 18,026 |  |  | $ | 13,325 |  |  | $ | 4,581 |  |  | 17,906 |
Other revenues |  |  |  |  |  | 1,107 |  |  |  |  |  |  | 884 |
Total revenues |  |  |  |  |  | $ | 19,133 |  |  |  |  |  |  | $ | 18,790 |
____________ (1) Hedging gains and losses, which are included in product sales, were not material for the three and nine months ended September 30, 2021 and 2020.

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration